Phase IIIRecruiting

Luspatercept in Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts

Bristol Myers Squibb·NCT05601234·Rare Diseases

Duration

18 months

Cost

Free to Patients

Phase

Phase III

Closes

Oct 2025

About This Trial

Evaluating luspatercept in lower-risk MDS patients with ring sideroblasts and transfusion dependence.

New York, NY

Houston, TX

Condition focus: Rare Diseases

Available in: US

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Only 23 spots remaining

Apply soon to secure your place.

Trial Summary

NCT NumberNCT05601234

SponsorBristol Myers Squibb

PhasePhase III

Duration18 months

ClosesOct 2025

ConditionRare Diseases